FDA Approves First Drug Created To Prevent Migraines

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

A new drug designed to fight chronic migraines could be on the market within a week.

The FDA approved Aimovig on Thursday.

It's designed to reduce the frequency of migraines which affect about 12% of Americans.

The drug works by blocking the activity of a genetic molecule involved in migraine attacks.

Patients will be able to administer the drug through monthly injections at home.

The drug requires a prescription it's expected to come with a price tag of $575, but may be covered by insurance.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.